Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) reported second-quarter 2026 net product revenue of approximately $13.5 million, a significant increase from $2 million in the year-ago period. The growth was primarily driven by approximately $11 million in net sales of TONMYA, the company's recently approved fibromyalgia treatment.
During the quarter, TONMYA recorded 12,592 total prescriptions, up 100% sequentially. New patient prescriptions increased 36%, and refills rose 207%, indicating strong patient adoption and adherence. The drug currently has coverage representing approximately 136 million lives across commercial, managed Medicare, and Medicaid channels. This coverage is expected to expand to approximately 145 million lives when a managed Medicare agreement takes effect on Jan. 1, 2027, potentially increasing market access.
Beyond commercial progress, Tonix continues to advance its clinical pipeline. The company has enrolled the first patient in the potentially pivotal Phase 2 HORIZON study of TNX-102 SL for major depressive disorder. Additionally, Tonix is preparing to begin an adaptive Phase 2 field study of TNX-4800 for Lyme disease prevention in the first quarter of 2027, pending final FDA review and agreement on the protocol. These developments underscore the company's commitment to addressing high unmet medical needs in central nervous system (CNS) and immunology.
Financially, Tonix ended the quarter with approximately $176.2 million in cash and cash equivalents. The company stated that its resources, together with third-quarter equity proceeds to date, are expected to fund planned operations and capital expenditures into early second-quarter 2027, providing a solid runway for ongoing programs.
The strong sales performance of TONMYA is particularly noteworthy as it is the first new treatment for fibromyalgia in more than 15 years. This milestone highlights the company's successful entry into the commercial market. The expansion of insurance coverage and rising prescription numbers suggest growing acceptance among healthcare providers and patients, which could translate into sustained revenue growth.
Tonix Pharmaceuticals is a fully-integrated, commercial-stage biotechnology company focused on CNS and immunology treatments. Its CNS commercial infrastructure supports marketed products, including acute migraine products Zembrace SymTouch and Tosymra. The company is also exploring the potential of TONMYA in Phase 2 clinical trials for major depressive disorder and acute stress disorder. Additionally, its CNS portfolio includes TNX-2900, which is Phase 2 ready for Prader-Willi syndrome, a rare disease. In immunology, Tonix is advancing TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for preventing kidney transplant rejection.
The company's product development candidates are investigational drugs or biologics; their efficacy and safety have not been established, and they have not been approved for any indication. Investors and stakeholders can monitor these developments as Tonix continues to build on its commercial and clinical momentum. For more information, visit https://nnw.fm/6Yytj.
